Expert Cancer Panel: Relapsed T-cell / Histiocyte rich B-cell Lymphoma (THRLBCL)

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 10/9/2021

58-year-old female with relapsed T-cell / Histiocyte rich B-cell Lymphoma (THRLBCL).

Summary:
- For a patient with T-cell histiocytic rich B cell lymphoma that is primary treatment refractory, the panel recommends salvage chemoimmunotherapy (RICE, R-Gem-Ox, or RDHAP) followed by autologous stem cell transplant in chemotherapy sensitive, transplant eligible patients.
- For patients who are transplant ineligible, options include clinical trials (like the ones for CAR-T), polatuzumab/bendamustine/rituximab, and tafasitamab/lenalidomide.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next